---
title: "Replimune Group, Inc. (REPL.US) — 公司概况"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/REPL.US/overview.md"
symbol: "REPL.US"
name: "Replimune Group, Inc."
parent: "https://longbridge.com/zh-CN/quote/REPL.US.md"
datetime: "2026-04-05T10:33:46.642Z"
locales:
  - [en](https://longbridge.com/en/quote/REPL.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/REPL.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/REPL.US/overview.md)
---

> 支持的语言: [English](https://longbridge.com/en/quote/REPL.US/overview.md) | [繁體中文](https://longbridge.com/zh-HK/quote/REPL.US/overview.md)


# Replimune Group, Inc. (REPL.US) — 公司概况

## 基本信息

| 项目 | 详情 |
|------|--------|
| 行业 | Biotechnology |
| 交易所 | US Market |
| 地址 | 500 Unicorn Park Drive, Suite 303, Woburn, Massachusetts, United States |
| 官网 | [www.replimune.com](https://www.replimune.com) |

## 公司简介

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company’s proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells.

## 核心管理层

| 名称 | 职位 |
|------|-------|
| Sushil Patel | CEO & Director |
| Philip Astley-Sparke | Executive Chairman |
| Emily Luisa Hill | Chief Financial Officer |
| Konstantinos Xynos | Chief Medical Officer |
| Andrew Schwendenman | Chief Accounting Officer & Treasurer |
| Dieter Weinand | Lead Independent Director |
| Joseph P. Slattery | Independent Director |
| Christy J. Oliger | Independent Director |

## 主要股东

| 名称 | 占比 | 报告日期 |
|------|-------|-------------|
| Baker Bros. Advisors LP | 13.38% | 2025-12-31 |
| T. Rowe Price Group, Inc. | 10.01% | 2025-12-31 |
| RTW Investments, LP | 8.65% | 2025-12-31 |
| BlackRock, Inc. | 7.35% | 2025-12-31 |
| The Vanguard Group, Inc. | 4.57% | 2025-12-31 |
| State Street Global Advisors, Inc. | 4.47% | 2025-12-31 |
| FMR LLC | 3.61% | 2025-12-31 |
| Forbion Capital Partners B.V. | 3.40% | 2025-12-31 |
| D. E. Shaw & Co., L.P. | 3.12% | 2025-12-31 |
| The Toronto-Dominion Bank | 2.70% | 2025-12-31 |


---

> **免责声明: 本文仅供参考，不构成任何投资建议。**